Abstract
Summary
Partial adherence in osteoporosis increases the risk for fragility fracture and has considerable impact on cost-effectiveness. This review highlights a number of avenues for further research, such as improved definition of thresholds of compliance and persistence, as well as gap length, offset times, and fraction of benefit.
Introduction
A number of economic models have been developed to evaluate osteoporosis therapies and support decisions regarding efficient allocation of health care resources. Adherence to treatment is seldom incorporated in these models, which may reduce their validity for decision-making since adherence is poor in real-world clinical practice.
Methods
An ad hoc working group of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis met to review key issues concerning the incorporation of partial adherence in health economic models.
Results
Observational data have shown that poor adherence is associated with an increase in the risk for fragility fracture. Health economic modelling indicates that full adherence is associated with more quality-adjusted life years gained than partial adherence, as well as higher treatment costs and lower fracture-related costs. Although adherence appears as an important driver of cost-effectiveness, the effect is dependent on a range of other variables, such as offset time, fraction of benefit, fracture risk, fracture efficacy, fracture-related costs, and drug cost, some of which are poorly defined. Current models used to evaluate cost-effectiveness in osteoporosis may oversimplify the contributions of compliance and persistence.
Conclusion
Partial adherence has a significant impact on cost-effectiveness. Further research is required to optimise thresholds of compliance and persistence, the impact of gap length, offset times, and fraction of benefit.
Similar content being viewed by others
References
International Osteoporosis Foundation (2009) Facts and statistics about osteoporosis and its implications. www.iofbonehealth.org/facts-and-statistics.html. Accessed 10 August 2009
Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238
Borgstrom F, Kanis JA (2008) Health economics of osteoporosis. Best Pract Res Clin Endocrinol Metab 22:885–900
Zethraeus N, Borgstrom F, Strom O et al (2007) Cost-effectiveness of the treatment and prevention of osteoporosis–a review of the literature and a reference model. Osteoporos Int 18:9–23
Strom O, Borgstrom F, Kanis JA et al (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23–34
Kanis JA, Jonsson B (2002) Economic evaluation of interventions for osteoporosis. Osteoporos Int 13:765–767
Kanis JA, Adams J, Borgstrom F et al (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15
Kanis JA, Oden A, Johansson H et al (2009) FRAX and its applications to clinical practice. Bone 44:734–743
Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47
Lekkerkerker F, Kanis JA, Alsayed N et al (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 18:1311–1317
Kendler DL, Ringe JD, Ste-Marie LG et al (2009) Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Osteoporos Int 20:1895–1902
Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896–905
Schousboe JT, Dowd BE, Davison ML et al (2010) Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int 21:1899–1909
Gallagher AM, Rietbrock S, Olson M et al (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569–1575
Borgstrom F, Strom O, Coelho J et al (2010) The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 21:339–349
Borgstrom F, Strom O, Coelho J et al (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495–505
Jonsson B, Strom O, Eisman JA et al (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967–982
Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123
Rossini M, Bianchi G, Di MO et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921
Ziller V, Wetzel K, Kyvernitakis I et al (2010) Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene. Climacteric 14:228–235
Huas D, Debiais F, Blotman F et al (2010) Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment. BMC Womens Health 10:26
Alegre P, Arnould B, Spizak C et al. (2010) Use of qualitative research to identify determinants of persistence for anti-osteoporotic treatments. Presented at the 13th ISPOR Annual European Conference, Prague, Czech Republic, 6–9 November 2010
Reginster JY, Felsenberg D, Cooper C et al (2006) A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int 17:159–166
Silverman SL, Schousboe JT, Gold DT (2011) Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 22:21–26
Cramer JA, Gold DT, Silverman SL et al (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031
Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928
Landfeldt E, Borgstrom F, Robbins S et al (2010) Adherence to treatment of osteoporosis in Sweden: The Swedish Adherence Register Analysis (SARA). P605. Osteoporos Int 21(suppl 1):S252
Li L, Roddam A, Gitlin M et al (2010) Retrospective analysis of persistence to anti-osteoporosis medications in the UK General Practice Research Database. P606. Osteoporos Int 21(suppl 1):S252
Breart G, Jakob FJ, Palacios S et al (2010) New interim analysis of a prospective observational cohort study of patients treated wth strontium ranelate. P416. Osteoporos Int 21(suppl 1):S166
Rabenda V, Hiligsmann M, Reginster JY (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 10:2303–2315
Siris ES, Selby PL, Saag KG et al (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13
Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022
Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818
Rabenda V, Reginster JY (2010) Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporos Int 21:1993–2002
Simpson SH, Eurich DT, Majumdar SR et al (2006) A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333:15
Curtis JR, Delzell E, Chen L et al. (2010) The relationship between bisphosphonate adherence and fracture: Is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res (in press)
McCloskey E, deTakats D, Orgee J et al (2005) Characteristics associated with non-persistence during daily therapy - experience from the placebo wing of a community-based clinical trial. J Bone Miner Res 20(suppl):S282
Weycker D, Macarios D, Edelsberg J et al (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645–1652
Hiligsmann M, Rabenda V, Gathon HJ et al (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202–210
Hiligsmann M, Rabenda V, Bruyere O et al (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96:170–177
Hiligsmann M, Gathon HJ, Bruyere O et al (2010) Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 13:394–401
Ivergard M, Strom O, Borgstrom F et al (2010) Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone 47:966–974
Stevenson M, Jones ML, De NE et al (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9:1–160
Kanis JA, McCloskey EV, Jonsson B et al (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fracture in postmenopausal women. Arch Osteoporos 5:19–48
Cotte FE, Fardellone P, Mercier F et al (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145–155
Acknowledgements
This paper was derived from a working group meeting on 1 December 2010 supported by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). We would like to thank the following for their valuable input to this paper: P. Alegre, E. Badamgarav, S. Corcaud, W. Dere, and B. Mitlak.
Conflicts of interest
C. Cooper received consulting fees and paid advisory boards for Alliance for Better Bone Health, GlaxoSmithKline, Roche, Merck Sharp and Dohme, Lilly, Amgen, Wyeth, Novartis, Servier, and Nycomed. M. Hiligsmann received research grants and/or lecture fees from Amgen, Servier, and Novartis. J.A. Kanis received consulting fees, paid advisory boards, lecture fees, and/or grant support from the majority of companies concerned with skeletal metabolism. V. Rabenda received research grants from Servier and Nycomed. J-Y. Reginster received consulting fees, paid advisory boards, lecture fees, and/or grant support from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, Theramex, UCB, Merck Sharp and Dohme, Rottapharm, IBSA, Genevrier, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Novo-Nordisk, and Bristol Myers Squibb. R. Rizzoli received paid advisory boards and lecture fees for Merck Sharp and Dohme, Eli Lilly, Amgen, Wyeth, Novartis, Servier, Nycomed, and Danone.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kanis, J.A., Cooper, C., Hiligsmann, M. et al. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22, 2565–2573 (2011). https://doi.org/10.1007/s00198-011-1668-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-011-1668-0